NovaBone Products Relocates to Meet Increasing Demand for Its Bioengineered Products
JACKSONVILLE, Fla.–(BUSINESS WIRE)–NovaBone Products, LLC has announced the relocation of its operations division to expanded and upgraded facilities where it will meet increasing demands of higher sales to a more geographically diverse distributor network.
NovaBone Products is a privately-held company and a leader in developing bio-engineered bone graft substitutes to meet the specialized demands of orthopedic and dental surgeons.
Located in the Progress Corporate Park in Alachua, Florida, the new facility has been effectively designed to facilitate the needs of a growing medical-device company. More than twice the size of the former operations location, the new facility increases productivity for both manufacturing and management functions.
Designed to meet the same ISO 13485 certifications as the prior relocation, the move was completed without disruption of service.
An updated product storage area was specifically constructed with mechanisms that satisfy a comprehensive disaster prevention system, as well as NovaBone’s enhanced security measures. The area further improves inventory handling, including shipment to customers.
“The manufacturing area is double that of our previous facility,” cites David Gaisser, Vice President of Operations. “This provides for an improved product flow and more efficient production.”
Established in 2002, NovaBone Products develops bone graft substitutes based on advancements in biomedical engineering.
Since its inception, NovaBone has developed numerous formulations and delivery systems of its patented, bioactive technology platform that result in accelerated bone growth. In total, the company’s exclusively formulated bone graft substitute has been used for the repair of osseous defects throughout the skeletal system for over a decade in more than a million clinical applications with unparalleled success validating the safety and efficacy of NovaBone’s technology.
NovaBone Products, LLC, Jacksonville
Arthur C. Wotiz, CEO, 904-807-0150